Whistleblower Says Celgene Bribed Docs To Sell Cancer Meds

Law360, New York (February 6, 2014, 7:59 PM EST) -- A former sales representative for Celgene Corp. is accusing the drugmaker of paying kickbacks to doctors for prescribing its cancer drugs Thalomid and Revlimid, and of marketing them for off-label uses that government programs including Medicare ended up paying for, according to court documents unsealed Thursday.

Relator Beverly Brown, who worked for Celgene for a decade starting in 2001, claimed that although the two drugs were only narrowly approved to treat multiple myeloma — a form of cancer that affects the bone marrow — they were...
To view the full article, register now.




Case Information

Case Title

United States of America et al v. Celgene Corporation

Case Number



California Central

Nature of Suit

Other Statutory Actions


R. Gary Klausner

Date Filed

April 27, 2010

Law Firms


Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.